Last $4.25 USD
Change Today -0.20 / -4.49%
Volume 613.4K
XOMA On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 1:52 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

xoma corp (XOMA) Snapshot

Open
$4.44
Previous Close
$4.45
Day High
$4.49
Day Low
$4.17
52 Week High
03/4/14 - $9.57
52 Week Low
05/8/13 - $3.02
Market Cap
453.2M
Average Volume 10 Days
1.9M
EPS TTM
$-1.40
Shares Outstanding
106.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for XOMA CORP (XOMA)

Related News

No related news articles were found.

xoma corp (XOMA) Related Businessweek News

No Related Businessweek News Found

xoma corp (XOMA) Details

XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. Its proprietary products comprise gevokizumab, a humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta, which is in Phase III studies for non-infectious uveitis, Behçet’s uveitis, pyoderma gangrenosum, active non-infectious anterior scleritis, cardiovascular disease, Schnitzler syndrome, and other diseases, as well as diseases under the neutrophilic dermatoses designation; and various proof-of-concept studies, including polymyositis/dermatomyositis, Schnitzler syndrome, and giant cell arteritis. The company’s proprietary products also include XOMA metabolic activating, sensitizing, and antagonizing/deactivating antibodies that are in preclinical stage for the treatment of diabetes patients; XOMA 3AB, a multi-antibody product for the treatment of human botulism poisoning; and XOMA 629, a topical anti-bacterial product for the treatment of human immune system. In addition, it develops ACEON, an angiotensin converting enzyme inhibitor product; FDC1, a perindopril arginine and amlodipine besylate product; and HCD122 and LFA102 programs for the treatment of cancer. Further, the company licenses Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX antibody discovery, optimization, and development technologies. It has collaboration agreements with Les Laboratoires Servier; National Institute of Allergy and Infectious Diseases; Takeda Pharmaceutical Company Limited; Novartis AG; Pfizer Inc.; and Margaux Biologics, Inc. The company was founded in 1981 and is headquartered in Berkeley, California.

168 Employees
Last Reported Date: 03/12/14
Founded in 1981

xoma corp (XOMA) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $489.3K
Founder, Chief Scientific Officer, Executive ...
Total Annual Compensation: $417.1K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $347.2K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $391.4K
Chief Commercial Officer and Vice President
Total Annual Compensation: $380.0K
Compensation as of Fiscal Year 2013.

xoma corp (XOMA) Key Developments

XOMA Corporation to Approve Amendments to Certificate of Incorporation

XOMA Corporation announced that the annual general meeting to be held on May 22, 2014, the board to approve an amendment to the Company's Certificate of Incorporation to increase the number of authorized shares of the company's common stock, par value $0.0075 per share, by an additional 138,666,666 to 277,333,332 shares.

XOMA Corporation Reports Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2013; Provides Cash Flow Guidance for the Year 2014

XOMA Corporation reported consolidated earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company's total revenues were $12,534,000 compared to $7,392,000 a year ago. Loss from operations was $15,580,000 compared to $12,619,000 a year ago. Net loss before taxes was $52,298,000 compared to net income before taxes of $2,365,000 a year ago. Net loss was $52,299,000 or $0.55 per basic and diluted share compared to net income of $2,365,000 or $0.03 per basic and diluted share a year ago. The increase in the fourth quarter and full-year 2013 Revenue was due primarily to the receipt of license and collaboration fees, which were offset by reductions in contract revenue and related expenses from NIAID government contracts and from reimbursements by Servier for gevokizumab-related activities. Excluding the non-cash revaluation of contingent warrant liabilities, the net loss for the three months ended December 31, 2013, was $17.0 million, or $0.18 per share. For the year, the company's total revenues were $35,451,000 compared to $33,782,000 a year ago. Loss from operations was $58,205,000 compared to $56,624,000 a year ago. Net loss before taxes was $124,072,000 compared to $71,139,000 a year ago. Net loss was $124,058,000 or $1.43 per basic and diluted share compared to $71,065,000 or $1.10 per basic and diluted share a year ago. The full-year net losses in 2013 and 2012 included $61.0 million and $9.2 million, respectively, in non-cash revaluation of contingent warrant liabilities, which resulted primarily from the appreciation of company’s stock price. Excluding those revaluations, the net loss for 2013 was $63.0 million, or $0.72 per share, and the net loss for 2012 was $61.9 million, or $0.96 per share. For the year 2014, the company anticipates cash used in ongoing operating activities during 2014 will be approximately $55.0 million to $60.0 million, primarily reflecting the costs associated with conducting the gevokizumab three Phase 3 clinical trials in the EYEGUARD program and the costs associated with conducting a Phase 3 clinical trial in patients with pyoderma gangrenosum.

XOMA Corporation Provides Update on Gevokizumab Proof-of-Concept Program

XOMA Corporation provided an update on its gevokizumab development program. Based on results from the company's Phase 2 program in patients with erosive osteoarthritis of the hand (EOA), XOMA does not intend to launch pivotal development for the broad EOA indication. The company will conduct a review of the full dataset to determine if there is a segment of the patient population that best responds to gevokizumab therapy prior to initiating any potential additional clinical studies in this indication. Gevokizumab appeared to be well tolerated, and the most common adverse events were comparable between both the gevokizumab and placebo groups. XOMA will continue to focus its efforts on completing the EYEGUARD(TM) Phase 3 clinical program, preparing to initiate its Phase 3 program in patients with pyoderma gangrenosum (PG), and assessing gevokizumab in pilot studies of other rare diseases that are in need of new therapeutic options. The company conducted two separate double-blind, placebo-controlled clinical studies in patients with EOA. The first study (Study 160) enrolled 85 patients who were diagnosed with EOA and who had a high-sensitivity C-reactive protein (CRP) level >=2.5 mg/L. CRP is recognized as a biomarker for generalized inflammation. The second study (Study 162) enrolled 92 patients who met the criteria for the first study but did not have elevated CRP. In both studies, patients were randomized 2:1 to receive either gevokizumab 60mg or placebo, dosed subcutaneously once monthly. Both studies were designed to determine if gevokizumab could improve the pain, stiffness, and physical function associated with EOA, based upon the Australian/Canadian Osteoarthritis Hand Index (AUSCAN(TM)) scoring scale. AUSCAN is a validated self-administered questionnaire specifically designed to assess the three dimensions of pain, disability, and joint stiffness of osteoarthritis of the hand using a series of 15 questions. Study 160 assessed the change in AUSCAN score from baseline at Days 84 and 168 in addition to assessing improvements of the effected joints from baseline using radiographic and MRI images taken at Days 84 and 168. Study 162 assessed the change in AUSCAN score from baseline at Day 84, the results in the second study did not show the same strength as the Day 84 results from Study 160. The initial results from Study 160 showed separation between the gevokizumab and placebo scores favoring gevokizumab over the 84-day period. While the gevokizumab-treated patients continued to show an improvement in all AUSCAN measures over their baseline scores after 168 days of therapy, the placebo treated patients showed a greater improvement over the final three months of the study, eliminating the separation seen between placebo and actively treated patients by the Day 168 time point. The company's primary analyses and other objective measures, such as MRIs and radiographs, did not suggest a significant drug-related benefit after six months. The company has begun analyses of relevant patient subgroups, and these data have shown placebo response was driven by patients with milder disease at baseline. Comparisons of patients with more severe pain (visual analog scale >= 75/100) at baseline show a consistent trend favoring gevokizumab in all components of their AUSCAN scores. In both proof-of-concept studies, gevokizumab demonstrated a statistically significant effect on CRP levels over the full study periods. It is possible these observations, as well as further analyses, could provide a reasonable group to study in future trials but it is too early to tell at this point. Gevokizumab was generally well tolerated, and there were no drug-related serious adverse events reported in these studies. The most common adverse events were headache, pain, arthralgia, urinary tract infections, upper respiratory tract infections and pneumonia, and they were comparable between gevokizumab and placebo.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XOMA:US $4.25 USD -0.20

XOMA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
BioInvent International AB kr2.99 SEK -0.01
Dyax Corp $6.89 USD -0.385
Genmab A/S kr203.40 DKK -4.60
Intrexon Corp $19.85 USD -1.25
MorphoSys AG €63.69 EUR -0.55
View Industry Companies
 

Industry Analysis

XOMA

Industry Average

Valuation XOMA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.9x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 8.8x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact XOMA CORP, please visit www.xoma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.